Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. But with promising early results from a phase 3 study in certain ...

Merck (NYSE:MRK) said a Phase 3 study of its drug Keytruda in the treatment of a certain type of ovarian cancer met its primary endpoint of progression-free survival, but not its secondary ...

Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors.

Keytruda is not approved to treat ovarian cancer. Sunday, Merck announced the first presentation of data from the Phase 2 waveLINE-007 trial evaluating zilovertamab vedotin in combination with ...

Merck (NYSE:MRK) announced Thursday that its bestselling therapy, Keytruda, as part of a combination regimen, reached the primary endpoint in a Phase 3 trial for a certain type of ovarian cancer.

Merck’s Keytruda shows promise in ovarian cancer trial. RAHWAY, N.J. – Merck & Co., Inc., a global healthcare leader, announced positive results from its Phase 3 KEYNOTE-B96 trial, which could ...

Merck & Co – known as MSD outside the US and Canada – has shared promising results from a late-stage study of its anti-PD-1 therapy Keytruda (pembrolizumab) in ovarian cancer. The phase 3 KEYNOTE-B96 ...

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers.

References: Merck announces phase 3 KEYNOTE-B96 trial met primary endpoint of progression-free survival (PFS) in patients with platinum-resistant recurrent ovarian cancer whose tumors expressed PD ...

Merck’s Keytruda shows promise in ovarian cancer trial. RAHWAY, N.J. – Merck & Co., Inc., a global healthcare leader, announced positive results from its Phase 3 KEYNOTE-B96 trial, which could ...

Ovarian cancer is a leading cause of cancer death among women, with an estimated 324,603 new cases and approximately 206,956 deaths globally in 2022. In the U.S., approximately 20,890 new cases ...